Establishment Labs Launches Preservé™
18 Fevereiro 2025 - 10:00AM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness in breast aesthetics and reconstruction, announced it
has launched Preservé™ in Brazil, the first country in its global
rollout. Preservé is the second product in the Company’s minimally
invasive platform, building upon the technologies and techniques
developed with Mia Femtech®, Establishment Labs’ minimally invasive
experience.
“These are not small innovations, this is an entirely new era
for aesthetic breast surgery,” said Juan José Chacón-Quirós,
Founder and CEO of Establishment Labs. “Whereas Mia® made minimally
invasive breast aesthetics possible for women looking for a one to
two cup enhancement, Preservé allows less invasive breast surgery
for the day-to-day breast augmentation patient.”
“Historically, many women have not been convinced by traditional
methods and legacy techniques,” Mr. Chacón-Quirós continued. “With
Mia and Preservé, we have solutions that address these concerns.
The technology platform of breast tissue preservation allows
plastic surgeons to create natural results with less disruption of
the patient’s breast tissue. By improving safety profiles, recovery
times, and achieving the breast aesthetic patients are looking for,
breast augmentation may now be possible for women that otherwise
never would have considered it — as well as making the decision
easier for many who were already considering. After Brazil,
Preservé will rollout globally over the next few years, and this
should contribute to top line growth and profitability.”
Preservé was designed to preserve breast tissue during aesthetic
breast surgery, maintaining the structural anatomy and function of
the breast for more stable and natural outcomes when compared to
traditional breast augmentation. Preservé leverages Establishment
Labs’ proprietary minimally invasive surgical tools coupled with
the Ergonomix2 implants, which feature the patented SmoothSilk®
surface, designed for enhanced biocompatibility and softness, and
which are unique in the industry as their shape adapts as the body
changes position. Preservé is intended for primary augmentations up
to four cups, hybrid augmentations, and mastopexy
augmentations.
“Breast tissue preservation is a new paradigm in breast
aesthetics. With less invasive breast procedures made possible by
technology pioneered by Establishment Labs, we can address many of
the complications that lead to reoperations,” said Dr Kamakshi
Zeidler, San Francisco plastic surgeon and head of the Femtech
board of Establishment Labs. “Preservé is an incredible new choice
for women considering breast augmentation because it speaks to many
of their aspirations, including smaller scars, quicker recovery,
maintaining breast sensation, and avoiding unnecessary
reoperations.”
The commercial launch of Preservé took place last weekend at the
Brazilian Breast Meeting in Rio de Janeiro with over 300 surgeons
in attendance and included live surgery and academic sessions. This
year additional launches of Preservé are planned around the
world.
The medical devices used in Preservé are not yet approved for
commercial distribution in the United States.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device
company dedicated to improving women’s health and wellness in
breast aesthetics and reconstruction through the power of science,
engineering, and technology. The Company offers a portfolio of
solutions for breast health, breast aesthetics, and breast
reconstruction in over 90 countries. With over four million Motiva
® devices delivered to plastic and reconstructive surgeons since
2010, the Company’s products have created a new standard for safety
and patient satisfaction. The company’s minimally invasive platform
consists of Mia Femtech®, a unique minimally invasive experience
for breast harmonization, and Preservé™, a breast tissue preserving
and minimally invasive technology for breast augmentation, revision
augmentation and mastopexy augmentation. GEM® is a next generation
minimally invasive system for gluteal ergonomic modeling currently
undergoing an IRB approved pivotal study. The Motiva Flora® tissue
expander is used to improve outcomes in breast reconstruction
following breast cancer and is the only regulatory-approved
expander in the world with an integrated port using radio-frequency
technology that is MRI conditional. Zensor™ is an RFID technology
platform used to safely identify implantable devices from outside
the body, and includes the company’s first biosensor Zenº™,
currently part of an IRB approved pivotal study to measure core
breast temperature. These solutions are supported by over 200
patents applications in 20 separate patent families worldwide and
over 100 scientific and clinical studies and publications in peer
reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our
website for additional information at
www.establishmentlabs.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250218369358/en/
Investor/Media Contact: Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Establishment Labs (NASDAQ:ESTA)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025